Patricia Corey-Lisle
Coventry
Summary
- Market Access, Health Economics, Measurement professional with 22+ years of pharmaceutical and biopharmaceutical industry experience.
- Specialty areas/therapeutic areas include: Neurology, Psychiatry, Oncology, Immunosciences, Virology, Ophthalmics, Hematology.
- Has demonstrated experience with building and maintaining highly effective teams
- A solid track record of collaborating with internal and external stakeholders to deliver commercially successful value propositions in high barrier market access environment
- An established Outcomes Scientist with robust research track record, numerous peer reviewed manuscripts, abstracts and presentations
- Experience across multiple therapeutic areas, including Orphan and Rare Disease
Overview
32
32
years of professional experience
Work History
Expert PCOR Scientist
Genentech Usa
11.2022 - Current
- Performed research into study topics to increase knowledge and to provide valuable contributions at a study/product level (predominantly oncology)
- Piloting robust Disease Strategy Focus as an experiment in efficient strategic coverage in Chronic Kidney Disease
- Wrote research papers, regulatory documents, reports, reviews, and summaries for oncology and optimization projects
- Member of Neuroscience Decentralized Trial workgroup
Global Head of Patient Centered Outcomes Research
Genentech Usa
03.2019 - 11.2022
- Managed Team of approx 40 Measurement Scientists to support Global Portfolio
- Member of the PDD Leadership Team
- Worked with team to identify future trends and to ensure that we had upskilling of team to meet future needs
- First team to pilot "Agile" Matrix organization within PDD (successful experiment) and development of tools to support flexible resourcing
Head Pricing Strategy, Systems, And Health Economics (VP)
Shire
01.2017 - 10.2018
- Developed new group mission and objectives to provide data analytics and support for pricing and access, in partnership with Global Market Access Leads and Franchise
- Led group that successfully developed pricing policy, exception process and achieved 90% success in alignment of Pricing Guidance for full portfolio (Baxalta and Shire)
- Focus on Rare Diseases (Hereditary Angioedema, Hunter's Syndrome, Hemophilia), Oncology (Breast, Pancreatic, Melanoma, NSCLC), and Specialty Pharmacy (ADHD, Ophthalmology)
Head, Global Value Strategy Access (GVSA) Ophthalmics, Oncology, Neuroscience (VP)
Shire
10.2016 - 12.2017
In Ophthalmics, Oncology, and Neuroscience:
- Ensure access to our medicines for patients around the world in a sustainable way at prices that reflect the value and promise these medicines bring to patients.
- Provide leadership for a high performing team delivering effective Patient Access Strategies that are supported by aligned functional Evidence Generation Plans
- Developing and managing Global Value Strategy Leads (GVSLs) responsible for demonstrating sustainable product value that build, expand or sustain (defend & maintain) specific therapies and enable local execution.
- Providing patient access expertise and deep market access insights anticipating changes in the external environment to ensure consistent GVSA support for effective Franchise Disease Area Strategies, Business Development and Early Stage Assets in designated areas.
Senior Director, Global Head of Pricing
Baxalta, INC
05.2015 - 12.2016
- Responsible for development of Pricing Workflow, Governance, and Systems support
- Lead for Strategic and Operational Pricing groups
- Development of Pricing Governance Dashboards, Pricing Plans
- Lead for Communication/Change management plans for new processes and procedures
Director, Global Health Economics
Amgen
09.2012 - 06.2014
- Established early health economics capability for the Global Health Economics Team
- Built up Value Evidence Generation Plans across Neuroscience Therapeutic Area (Schizophrenia, Migraine, Alzheimer's Dementia)
- Communicated plans effectively across complex matrix, obtained funding ($2.2M) to support the development of Neuroscience team (1 Director/1 Manager/1 Research Assistant/1 Graduate Intern)
- Presented Patient Reported Outcomes development plans to US and EU Regulatory Agencies to gain alignment
- Supported early Health Technology engagement strategy and submission
- Delivered methodologically sound research to suppport corporate objectives
Global Payer (Market Access) Lead
Amgen
01.2010 - 09.2012
- Dual Role as Global Health Economics and Global Payer Lead (Market Access) for a mature brand (2010 to 2012)
- Set Global Market Access Strategy and Value Evidence Plans for a challenging global brand (oncology supportive therapy)
- Successfully led team response to AHRQ Comparative Effectiveness Review
- Set strategy and delivered protocols to satisfy regulatory requirments for a Risk Evaluation Management (REMS) program
- Served a 4 month international job rotation during EU financial crisis to spearhead multiple HTS requests
Group Director, Health Economics And Outcomes Research
Bristol Myers Squibb
01.2008 - 01.2010
- Lead Position in Health Outcomes/Health Economics
- Therapeutic Area strategy lead across multiple areas
- Developed Global Health Economics Team to support pipeline and mature products (3 Director, 3 Associate Directors)
- Represented Global Health Economics strategy to upper management and for potential business opportunities
- Established key instrument development programs for schizophrenia, hepatitis C
Director Health Economics And Outcomes Research
Bristol Myers Squibb
01.2006 - 01.2008
- Support of multiple therapeutic areas
- Launch of 2 key product brands (neuroscience, oncology)
- Supervision and development of junior staff members (2 associate directors)
- Cross functional alignment around economic models (oncology, neuroscience) and Patient reported Outcomes strategy
- Execution of Value Evidence Generation plans and multiple peer reviewed publications, presentations, and abstracts
- Budget management
Associate Director Health Economics And Outcomes Research
Bristol Myers Squibb
01.2003 - 01.2006
- Product lead for Neuroscience and Virology Products
- Support for successful in line brand (schizophrenia)
- Execution of critical strategy, external collaborations, and research projects
- Multiple publications that provided measurable commercial support (Metabolic Syndrome in second generation antipsychotics; emerging indications)
Senior Health Outcomes Scientist
Eli Lilly Company
09.2000 - 09.2003
- Execution of Value Evidence Plan and successful launch of blockbuster antidepressant (Cymbalta)
- Establishment of external collaborations (academic and Key Opinion Leaders) for study concepts
- Communication of strategic vision within product team and support of scientific platform
- Completion of epidemiological studies (database) and economic models
- Mentoring of junior staff member
Adjunct Faculty Member
Indiana University, Purdue University, School of Medicine, Department of Public Health
01.2002 - 01.2004
- Instructor in Advanced Epidemiological Methods
Research Associate, faculty position
University of Maryland
07.1993 - 12.1999
- Position as Research Coordinator at Maryland Psychiatric Research Unit (Residential Inpatient Unit)
- Residency position in doctoral program, Dr. Alison Trinkoff
Education
Ph.D. - Research Methodology and Outcomes Evaluation
University of Maryland
Baltimore, MD2000
MSN - Adult Mental Health and Psychiatry, sub-specialization in Consultation Liaison Nursing
Yale University
New Haven, Connecticut 1993
BSN - Nursing
University of Hartford
West Hartford, CT1990
Skills
- Proven leader in strategy & planning
- Excellent communication skills
- Demonstrated ability to build teams and mentor junior staff members
- Successful Health Technology Assessment (HTA) strategy and execution
- Solid experience in developing pricing strategy, balancing value and profitability
- Sound methodology skills in all critical areas of Health Economics and Outcomes Research
- Development of novel endpoints (Patient-reported outcomes)
- Economic Modeling
- Database Studies
- Prospective Observational Studies (Comparative Effectiveness Research)
Publications
Corey-Lisle, PK, Desrosiers, MP, Collins, H, De la Orden, M. Payne, KA, Levache, CB, Dumont, P. (In press). Transfusions and patient burden in chemotherapy-induced anaemia inFrance. Therapeutic Advances in Medical Oncology.
Hill, JW, Shreay, S, McGarvey, N, De, AP, Hess, GP, Corey-Lisle, PK. (2013). Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits. Supportive Care Cancer. June. DOI 10.1007/s00520-013-1830-7
Reitan, JF, van Breda, A, Corey-Lisle, PK, Shreay, S, Cong, Z, Legg, J. (2013). Staff time and motion assessment for administration of Erythropoiesis-Stimulating Agents: A two-phase pilot study in clinical oncology practices. Clinical Drug Investigations. DOI 10:1007/s40261-013-0078-9
Reitan, JF, Kudrik, FJ, Fox, K. van Breda, A, Shreay, S, Corey-Lisle, PK. (2013). The burden of blood transfusion: A utilization and economic analysis-a pilot study in patients with chemotherapy-induced anemia (CIA). Journal Of Medical Economics, 16, 5 (1-6).
Shreay, S, Desrosiers, M-P, Corey-Lisle, P, Payne, K. (2012). A retrospective study to evaluate the time burden associated with outpatient red blood transfusions indicated for anemia due to concomitantly administered chemotherapy in cancer patients. Supportive Care in Cancer, online available December 2012. DOI 10.1007/s00520-012-1671-9
Berger, A, Lord, C, Corey-Lisle, PK, Williams, GR, Oster, G. (2012). Utilization and cost in clinical practice of darbepoetin alfa and epoetin alfa for anemia concomitant with chemotherapy. Clinical Therapeutics, 34, 6, 1350-1363.
Mojtabai, R, Corey-Lisle, PK, IP, EH, Kopeykina, I, Haeri, S, Cohen, LJ, Shumaker, S. (2012). Validation of the patient assessment questionnaire: a measure of treatment effectiveness for patients with schizophrenia and schizoaffective disorder. Psychiatric Research, 200,2-3, 857-866.
Corey-Lisle, PK, Peck R, MukhopadhyayP, Orsini L, Safikhani, S, Bell, J, Hortobagyi, G, Roche, H, Conte, P, Revicki, DA.(2012). Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. Cancer, 118:461–8.
Brook, RA, Kleinman, NL, Su, J, Corey-Lisle, PK, Iloeje, U. (2011) Absenteeism and productivity among employees being treated for Hepatitis C. American Journal of Managed Care , 17 (10): 657-664. Su,J,
Brook, RA, Kleinman, NL, Corey-Lisle, P. (2010). The Impact of Hepatitis C Virus Infection on WorkAbsence, Productivity, and Healthcare Benefit Costs. Hepatology, 52: 436-442
Owen, R. Sikich, L. Marcus, RN,. Corey-Lisle, P. Manos, G. McQuade, RD. Carson, WH. Findling, RL.(2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 124(6):1533-40
Ho, J, Zhang, L, Todorova, L, Whillans, F, Corey-Lisle, PK, Yuan, Y. (2009). Budget Impact Analysis of Ixabepilone used According to FDA Approved Labeling in Treatment-Resistant Metastatic Breast Cancer. J Manag Care Pharm. 15(6):467-75
Trivedi, MH, Corey-Lisle, PK, Guo, Z, Lennox, RD, Pikalov, A, Kim, E. (2009). Remission, Response without Remission and Nonresponse in Major Depressive Disorder: Impact on Functioning. International Clinical Psychopharmacology. 24(3):133-8.
Kolotkin, RL, Corey-Lisle, PK, Crosby, RD, Kan, HJ. (2008). Changes in weight and weight-related quality of life in a multicenter, randomized trial of aripiprazole versus standard of care. (2008) European Psychiatry 23 (8): 561-566.
Kolotkin, RL, Corey-Lisle, PK, Crosby, RD, Swanson, JS , Tuomari, AV, L’Italien, GL, Mitchell, JE. (2008). Impact of Obesity on Health-Related Quality of Life in Schizophrenia and Bipolar Disorder. Obesity16(4):749-54.
Cashin RP, Lui P, Hemels MEH, Corey-Lisle PK, Einarson TR. (2008). Advanced cutaneous malignant melanoma: A systematic review of pharmacoeconomic and quality of life articles. Value in Health, 11 (2), 259-271.
Lui, P, Cashin, R, Machado, M, Hemels, M, Corey-Lisle, PK, Einarson, TR. (2007) Treatments for metastatic melanoma: Synthesis of evidence from randomized trials. Cancer Treatment Reviews, 33(8):665-80.
Harley, C., Li, H., Corey-Lisle , PK, L’Italien , GJ, Carson, W., Hirschfeld, RMA. (2007) Influence of Medication Choice and Comorbid Diabetes: The Cost of Bipolar Disorder in a Privately Insured US Population. Social Psychiatry and Psychiatric Epidemiology, 42(9):690-7.
Berman, RM, Marcus, RN, Swanink, R, McQuade, RD, Carson, WH, Corey-Lisle, PK, Khan, A. (2007). The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind placebo-controlled study. J Clin Psych, 68 (6), 843-853.
Guo, JJ, Keck, PE, Corey-Lisle, PK, Li, H., Jiang, D., Jang, R, L’Italien, GJ.(2007). Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: A population-based case-control study, Pharmacotherapy, 27 (1), 27-35.
Pritchett, Y.L., Marciniak, M.D, Corey-Lisle, P.K., Berzon, R.A, Desaiah, D., Detke, M. (2007). Use of Effect Size to Determine Optimal Dose of Duloxetine in Major Depressive Disorder. Journal of Psychiatric Research, 41, 311-318.
Olfson, M, Marcus, SC, Corey-Lisle, PK, Tuomari, V, Hines, P, & L’Italien, GJ. (2006). Hyperlipidemia following treatment with second generation antipsychotic medication. American Journal of Psychiatry, 163, (10) 1821-1825.
Guo, JJ, Keck, PE, Corey-Lisle, PK, Li, H., Jiang, D., Jang, R, L’Italien, GJ.(2006). Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A population-based case-control study. Journal of Clinical Psychiatry, 67 (7), 1055-1061.
Kolotkin, RL, Crosby, RD, Corey-Lisle, PK, Li, H,. Swanson, JS. (2006). Performance of a Weight-Related Measure of Quality of Life in a Psychiatric Sample. Quality of Life Research, 15 (4) 587-596.
Brixner, DI, Oayyim, S., Corey-Lisle, PK, Tuomari, V, L’Italien, GJ, Stockdale, W, Oderda, GM. (2006). Real World Impact of Second Generation Antipsychotics on Weight Gain. Annals of Pharmacotherapy 40(4), 626-32.
Tandon, R, DeVellis, RF, Han, J, Li, H., Frangou, S, and Dursun, S, Beuzen, JN, Carson, W, Corey-Lisle, PK, Falissard, B, Jody, D, Kujawa, MJ, L’Italien, G, Marcus, RN, McQuade, RD, Ray, S, Van Peborgh, P. (2005). Validation of the Investigator’s Assessment Questionnaire, a new clinical tool for assessing response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatric Research, 136, 211-221.
Corey-Lisle, P.K., Nash, R., Stang, P., Swindle, R. (2004). Response, partial response, and non-response in primary care: An examination of baseline characteristics, treatment patterns, and outcomes. Archives of Internal Medicine, 164, 1197-1204.
Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A. (2004). Economic implications of treatment-resistant depression among employees. Pharmacoeconomics;22(6):363-73.
Greenberg, PE, Kessler, RC, Birnbaum, HG, Leong, SA, Lowe, SW, Berglund, PA, & Corey-Lisle, PK. (2003) The economic burden of depressive disorders in the United States: How did it change between 1990 and 2000? Journal of Clinical Psychiatry, 64 (12), 1465-1475.
Corey-Lisle, P.K. , Birnbaum, H., Greenberg, P., Marynchenko, M., Dube, S. (2003). The economic impact of olanzapine/fluoxetine combination therapy among patients treated for depression. Psychopharmacology Bulletin, 37 (3), 90-98.
Corey-Lisle PK, Birnbaum H, Greenberg P, Claxton AJ. (2002) Identification of Claims Data "Signature" and Economic Consequences for Treatment-Resistant Depression. Journal of Clinical Psychiatry, 63 (8), 717-726.
Corey-Lisle, P., Tarzian, A. J., Trinkoff, A.M., & Cohen, M.Z. (1999) Health Care Reform: Its effects on nurses. JONA: Journal of Nursing Administration, 29 (3), 30-37.
Lahti, A.C., Weiler, M.A., Corey, P.K., Lahti, R.A., Carlsson, A., Tamminga, C.A. (1998). Antipsychotic properies of the Partial Dopamine Agonist (-) -3PPP in Schizophrenia, Biological Psychiatry,43 (1), 2-11.
Hill, JW, Shreay, S, McGarvey, N, De, AP, Hess, GP, Corey-Lisle, PK. (2013). Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits. Supportive Care Cancer. June. DOI 10.1007/s00520-013-1830-7
Reitan, JF, van Breda, A, Corey-Lisle, PK, Shreay, S, Cong, Z, Legg, J. (2013). Staff time and motion assessment for administration of Erythropoiesis-Stimulating Agents: A two-phase pilot study in clinical oncology practices. Clinical Drug Investigations. DOI 10:1007/s40261-013-0078-9
Reitan, JF, Kudrik, FJ, Fox, K. van Breda, A, Shreay, S, Corey-Lisle, PK. (2013). The burden of blood transfusion: A utilization and economic analysis-a pilot study in patients with chemotherapy-induced anemia (CIA). Journal Of Medical Economics, 16, 5 (1-6).
Shreay, S, Desrosiers, M-P, Corey-Lisle, P, Payne, K. (2012). A retrospective study to evaluate the time burden associated with outpatient red blood transfusions indicated for anemia due to concomitantly administered chemotherapy in cancer patients. Supportive Care in Cancer, online available December 2012. DOI 10.1007/s00520-012-1671-9
Berger, A, Lord, C, Corey-Lisle, PK, Williams, GR, Oster, G. (2012). Utilization and cost in clinical practice of darbepoetin alfa and epoetin alfa for anemia concomitant with chemotherapy. Clinical Therapeutics, 34, 6, 1350-1363.
Mojtabai, R, Corey-Lisle, PK, IP, EH, Kopeykina, I, Haeri, S, Cohen, LJ, Shumaker, S. (2012). Validation of the patient assessment questionnaire: a measure of treatment effectiveness for patients with schizophrenia and schizoaffective disorder. Psychiatric Research, 200,2-3, 857-866.
Corey-Lisle, PK, Peck R, MukhopadhyayP, Orsini L, Safikhani, S, Bell, J, Hortobagyi, G, Roche, H, Conte, P, Revicki, DA.(2012). Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. Cancer, 118:461–8.
Brook, RA, Kleinman, NL, Su, J, Corey-Lisle, PK, Iloeje, U. (2011) Absenteeism and productivity among employees being treated for Hepatitis C. American Journal of Managed Care , 17 (10): 657-664. Su,J,
Brook, RA, Kleinman, NL, Corey-Lisle, P. (2010). The Impact of Hepatitis C Virus Infection on WorkAbsence, Productivity, and Healthcare Benefit Costs. Hepatology, 52: 436-442
Owen, R. Sikich, L. Marcus, RN,. Corey-Lisle, P. Manos, G. McQuade, RD. Carson, WH. Findling, RL.(2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 124(6):1533-40
Ho, J, Zhang, L, Todorova, L, Whillans, F, Corey-Lisle, PK, Yuan, Y. (2009). Budget Impact Analysis of Ixabepilone used According to FDA Approved Labeling in Treatment-Resistant Metastatic Breast Cancer. J Manag Care Pharm. 15(6):467-75
Trivedi, MH, Corey-Lisle, PK, Guo, Z, Lennox, RD, Pikalov, A, Kim, E. (2009). Remission, Response without Remission and Nonresponse in Major Depressive Disorder: Impact on Functioning. International Clinical Psychopharmacology. 24(3):133-8.
Kolotkin, RL, Corey-Lisle, PK, Crosby, RD, Kan, HJ. (2008). Changes in weight and weight-related quality of life in a multicenter, randomized trial of aripiprazole versus standard of care. (2008) European Psychiatry 23 (8): 561-566.
Kolotkin, RL, Corey-Lisle, PK, Crosby, RD, Swanson, JS , Tuomari, AV, L’Italien, GL, Mitchell, JE. (2008). Impact of Obesity on Health-Related Quality of Life in Schizophrenia and Bipolar Disorder. Obesity16(4):749-54.
Cashin RP, Lui P, Hemels MEH, Corey-Lisle PK, Einarson TR. (2008). Advanced cutaneous malignant melanoma: A systematic review of pharmacoeconomic and quality of life articles. Value in Health, 11 (2), 259-271.
Lui, P, Cashin, R, Machado, M, Hemels, M, Corey-Lisle, PK, Einarson, TR. (2007) Treatments for metastatic melanoma: Synthesis of evidence from randomized trials. Cancer Treatment Reviews, 33(8):665-80.
Harley, C., Li, H., Corey-Lisle , PK, L’Italien , GJ, Carson, W., Hirschfeld, RMA. (2007) Influence of Medication Choice and Comorbid Diabetes: The Cost of Bipolar Disorder in a Privately Insured US Population. Social Psychiatry and Psychiatric Epidemiology, 42(9):690-7.
Berman, RM, Marcus, RN, Swanink, R, McQuade, RD, Carson, WH, Corey-Lisle, PK, Khan, A. (2007). The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind placebo-controlled study. J Clin Psych, 68 (6), 843-853.
Guo, JJ, Keck, PE, Corey-Lisle, PK, Li, H., Jiang, D., Jang, R, L’Italien, GJ.(2007). Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: A population-based case-control study, Pharmacotherapy, 27 (1), 27-35.
Pritchett, Y.L., Marciniak, M.D, Corey-Lisle, P.K., Berzon, R.A, Desaiah, D., Detke, M. (2007). Use of Effect Size to Determine Optimal Dose of Duloxetine in Major Depressive Disorder. Journal of Psychiatric Research, 41, 311-318.
Olfson, M, Marcus, SC, Corey-Lisle, PK, Tuomari, V, Hines, P, & L’Italien, GJ. (2006). Hyperlipidemia following treatment with second generation antipsychotic medication. American Journal of Psychiatry, 163, (10) 1821-1825.
Guo, JJ, Keck, PE, Corey-Lisle, PK, Li, H., Jiang, D., Jang, R, L’Italien, GJ.(2006). Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A population-based case-control study. Journal of Clinical Psychiatry, 67 (7), 1055-1061.
Kolotkin, RL, Crosby, RD, Corey-Lisle, PK, Li, H,. Swanson, JS. (2006). Performance of a Weight-Related Measure of Quality of Life in a Psychiatric Sample. Quality of Life Research, 15 (4) 587-596.
Brixner, DI, Oayyim, S., Corey-Lisle, PK, Tuomari, V, L’Italien, GJ, Stockdale, W, Oderda, GM. (2006). Real World Impact of Second Generation Antipsychotics on Weight Gain. Annals of Pharmacotherapy 40(4), 626-32.
Tandon, R, DeVellis, RF, Han, J, Li, H., Frangou, S, and Dursun, S, Beuzen, JN, Carson, W, Corey-Lisle, PK, Falissard, B, Jody, D, Kujawa, MJ, L’Italien, G, Marcus, RN, McQuade, RD, Ray, S, Van Peborgh, P. (2005). Validation of the Investigator’s Assessment Questionnaire, a new clinical tool for assessing response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatric Research, 136, 211-221.
Corey-Lisle, P.K., Nash, R., Stang, P., Swindle, R. (2004). Response, partial response, and non-response in primary care: An examination of baseline characteristics, treatment patterns, and outcomes. Archives of Internal Medicine, 164, 1197-1204.
Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A. (2004). Economic implications of treatment-resistant depression among employees. Pharmacoeconomics;22(6):363-73.
Greenberg, PE, Kessler, RC, Birnbaum, HG, Leong, SA, Lowe, SW, Berglund, PA, & Corey-Lisle, PK. (2003) The economic burden of depressive disorders in the United States: How did it change between 1990 and 2000? Journal of Clinical Psychiatry, 64 (12), 1465-1475.
Corey-Lisle, P.K. , Birnbaum, H., Greenberg, P., Marynchenko, M., Dube, S. (2003). The economic impact of olanzapine/fluoxetine combination therapy among patients treated for depression. Psychopharmacology Bulletin, 37 (3), 90-98.
Corey-Lisle PK, Birnbaum H, Greenberg P, Claxton AJ. (2002) Identification of Claims Data "Signature" and Economic Consequences for Treatment-Resistant Depression. Journal of Clinical Psychiatry, 63 (8), 717-726.
Corey-Lisle, P., Tarzian, A. J., Trinkoff, A.M., & Cohen, M.Z. (1999) Health Care Reform: Its effects on nurses. JONA: Journal of Nursing Administration, 29 (3), 30-37.
Lahti, A.C., Weiler, M.A., Corey, P.K., Lahti, R.A., Carlsson, A., Tamminga, C.A. (1998). Antipsychotic properies of the Partial Dopamine Agonist (-) -3PPP in Schizophrenia, Biological Psychiatry,43 (1), 2-11.
Awards and Memberships
- AmgenGlobal Value and Access "Victory Award" for stellar Patient-reported Outcomes Strategy and successful FDA interaction, March, 2013
- Eli Lilly"Shining Star Award" from Global Sales and Marketing Organization for efficient adaptation of Value Evidence Plans to a new product, April, 2002
- Bravo Awards (2011, 2012, 2013) Top Observational Research Review Group Reviewer
- Appointment to Board of Directors, Howard County Mental Health Authority, May 2000.
- Sigma Theta Tau International, Nursing Honor Society, 1993
- International Society for Pharmacoeconomics and Outcome Research
- International Society for CNS Clinical Trials and Methodolgy, member of Negative Symptoms and Methodological Challenges in International Trials work groups
Timeline
Expert PCOR Scientist
Genentech Usa
11.2022 - Current
Global Head of Patient Centered Outcomes Research
Genentech Usa
03.2019 - 11.2022
Head Pricing Strategy, Systems, And Health Economics (VP)
Shire
01.2017 - 10.2018
Head, Global Value Strategy Access (GVSA) Ophthalmics, Oncology, Neuroscience (VP)
Shire
10.2016 - 12.2017
Senior Director, Global Head of Pricing
Baxalta, INC
05.2015 - 12.2016
Director, Global Health Economics
Amgen
09.2012 - 06.2014
Global Payer (Market Access) Lead
Amgen
01.2010 - 09.2012
Group Director, Health Economics And Outcomes Research
Bristol Myers Squibb
01.2008 - 01.2010
Director Health Economics And Outcomes Research
Bristol Myers Squibb
01.2006 - 01.2008
Associate Director Health Economics And Outcomes Research
Bristol Myers Squibb
01.2003 - 01.2006
Adjunct Faculty Member
Indiana University, Purdue University, School of Medicine, Department of Public Health
01.2002 - 01.2004
Senior Health Outcomes Scientist
Eli Lilly Company
09.2000 - 09.2003
Research Associate, faculty position
University of Maryland
07.1993 - 12.1999
Ph.D. - Research Methodology and Outcomes Evaluation
University of Maryland
MSN - Adult Mental Health and Psychiatry, sub-specialization in Consultation Liaison Nursing
Yale University
BSN - Nursing
University of Hartford
Similar Profiles
Roger KryerRoger Kryer
Therapeutic Area Mgr / Hematology at Genentech UsaTherapeutic Area Mgr / Hematology at Genentech Usa
Heather RossHeather Ross
Principal National Account Executive - PBMs at GenentechPrincipal National Account Executive - PBMs at Genentech
Russ BrennemanRuss Brenneman
Clinical Education Manager II at Genentech Inc.Clinical Education Manager II at Genentech Inc.
Madison FerraraMadison Ferrara
In Home Child Care at Alex Gierhart, Ryan GierhartIn Home Child Care at Alex Gierhart, Ryan Gierhart
Daniel CalcottDaniel Calcott
Warehouse worker at Lal & Sons Cash and CarryWarehouse worker at Lal & Sons Cash and Carry